Full high-throughput sequencing analysis of differences in expression profiles of long noncoding RNAs and their mechanisms of action in systemic lupus erythematosus

• Published in: Arthritis research & therapy Vol. 21; no. 1; p. 70
• Main Authors: Ye, Hui, Wang, Xue, Wang, Lei, Chu, Xiaoying, Hu, Xuanxuan, Sun, Li, Jiang, Minghua, Wang, Hong, Wang, Zihan, Zhao, Han, Yang, Xinyu, Wang, Jianguang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.03.2019; BioMed Central; BMC
• Subjects: Adult; Arthritis; Cells, Cultured; Computational Biology - methods; Development and progression; Diagnosis; Disease; Epigenetics; Expression profiles; Gender; Gene expression; Gene Expression Profiling - methods; Gene Ontology; Gene Regulatory Networks; Genetic aspects; Genomes; Health aspects; High-Throughput Nucleotide Sequencing - methods; High-throughput sequencing analysis; Humans; Identification and classification; Leukocytes, Mononuclear - metabolism; Long noncoding RNA; Lupus; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - genetics; Mechanisms; MicroRNAs - genetics; Middle Aged; Pathogenesis; Proteins; Psoriasis; RNA; RNA, Long Noncoding - genetics; RNA, Messenger - genetics; Systemic lupus erythematosus; Target recognition; China; Mechanisms; Expression profiles; Systemic lupus erythematosus; High-throughput sequencing analysis; Long noncoding RNA
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-019-1853-7

The specific function of long noncoding RNAs (lncRNAs) in systemic lupus erythematosus (SLE) and the mechanism of their involvement in related pathological changes remain to be elucidated, so, in this study, we analyzed the differences in the expression profiles of lncRNAs and their mechanisms of action in SLE using full high-throughput sequencing, bioinformatics, etc. methods. We used high-throughput sequencing to detect differences in the expression profiles of lncRNAs, miRNAs, and mRNAs in PBMCs from patients with SLE at the genome-wide level. Next, we predicted target genes of 30 lincRNAs (long intergenic noncoding RNAs) by constructing a coexpression network of differential lincRNAs and mRNAs and identified the role of lincRNAs. Then, we analyzed the coexpression network of 23 optimized lincRNAs and their corresponding 353 miRNAs, evaluated the cis- and trans-effects of these lincRNAs, and performed GO and KEGG analyses of target genes. We also selected 8 lincRNAs and 2 newly discovered lncRNAs for q-PCR validation and lncRNA-miRNA-mRNA analysis. Finally, we also analyzed respectively the relation between lncRNAs and gender bias in SLE patients using RT-qPCR, the relation between Systemic Lupus Erythematosus Disease Activity Index score and the "IFN signature" using ELISA, and the relation between the differential expression of lncRNAs and a change in the number of a cell type of PBMCs in SLE patients using RT-qPCR. The profiles of 1087 lncRNAs, 102 miRNAs, and 4101 mRNAs in PBMCs significantly differed between patients with SLE and healthy controls. The coexpression network analysis showed that the network contained 23 lincRNAs and 353 mRNAs. The evaluation of the cis- and trans-effects showed that the 23 lincRNAs acted on 704 target genes. GO and KEGG analyses of the target genes predicted the biological functions of the 23 lincRNAs. q-PCR validation showed 7 lincRNAs and 2 novel lncRNAs were identical to the sequencing results. The ceRNA network contained 7 validated lincRNAs, 15 miRNAs, and 155 mRNAs. In addition, the differential expression of lncRNAs may be gender dependent in SLE patients, SLE patients also exhibit a robust "IFN signature," and PBMCs exhibiting differential expression of lncRNAs may be due to a change in the number of a cell type. This work determined specific lncRNAs that play important biological functions in the pathogenesis of lupus and provided a new direction for diagnosis and treatment of disease.